# US 2018/0002421 A1 · Human monoclonal antibodies against orexin receptor type 1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0002421 A1
- Document ID: US20180002421A1
- Status: Published application
- Kind: A1
- Application number: 15/543,371
- Filed: 2016-01-14
- Published: 2018-01-04
- Earliest claimed: 2015-01-16
- Assignees: Inserm (Institut National De La Sante Et De La Recherche Medicale); Universite Paris Diderot—Paris 7; Institut Regional Du Cancer De Montpellier; Universite De Montpellier
- Applicants: Inserm (Institut National De La Sante Et De La Recherche Medicale); Universite Paris Diderot - Paris 7; Institut Regional Du Cancer De Montpellier; Universite De Montpellier
- Inventors: Alain COUVINEAU; Thierry VOISIN; Pascal NICOLE; Bruno ROBERT; Pierre MARTINEAU; Myriam CHENTOUF
- Web page: https://patentgrep.com/patent/US20180002421A1

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 35/00: Antineoplastic agents
- C07K 16/286: {against neuromediator receptors, e.g. serotonin receptor, dopamine receptor}
- C07K 16/30: from tumour cells
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to human monoclonal antibodies against orexin receptor type 1 (OX1R, hyprocretin 1) and uses thereof for the treatment of cancer. The antibodies are characterized by their CDRs: NYYMN, YISGSSRNIYYADFVKG, SNYDGMDV (Heavy chain) and AGTSSDVGGSNYVS, PGKAP, SSYTYYSTRV (Light Chain)) or the CDRS having at least 50% or 70% identity with the above listed sequences.

## Claims

### Claim 1

A human monoclonal antibody against OX1R comprising a heavy chain comprising i) a H-CDR1 having at least 50% identity with a H-CDR1 of C2, ii) a H-CDR2 having at least 50% identity with a H-CDR2 of C2 and iii) a H-CDR3 having at least 50% identity with a H-CDR3 of C2 of and/or a light chain comprising i) a L-CDR1 having at least 50% identity with a L-CDR1 of C2, ii) a L-CDR2 having at least 50% identity with a L-CDR2 of C2 and iii) a L-CDR3 having at least 50% identity with a L-CDR3 of C2 wherein
the H-CDR1 of C2 is defined by a sequence ranging from an amino acid residue at position 31 to an amino acid residue at position 35 in SEQ ID NO:1,
the H-CDR2 of C2 is defined by a sequence ranging from an amino acid residue at position 50 to an amino acid residue at position 66 in SEQ ID NO:1,
the H-CDR3 of C2 is defined by a sequence ranging from an amino acid residue at position 99 to an amino acid residue at position 109 in SEQ ID NO:1,
the L-CDR1 of C2 is defined by a sequence ranging from an amino acid residue at position 23 to an amino acid residue at position 36 in SEQ ID NO:2,
the L-CDR2 of C2 is defined by a sequence ranging from an amino acid residue at position 52 to an amino acid residue at position 58 in SEQ ID NO:2, and,
the L-CDR3 of C2 is defined by a sequence ranging from an amino acid residue at position 91 to an amino acid residue at position 100 in SEQ ID NO:2.

### Claim 2 (depends on 1)

The human monoclonal antibody of claim 1 comprising a heavy chain comprising i) a H-CDR1 having at least 50% identity with the H-CDR1 of C2, ii) a H-CDR2 having at least 50% identity with the H-CDR2 of C2 and iii) a H-CDR3 having at least 50% identity with the H-CDR3 of C2 and a light chain comprising i) a L-CDR2 having at least 50% identity with the L-CDR1 of C2, ii) a L-CDR2 having at least 50% identity with the L-CDR2 of C2 and iii) a L-CDR3 having at least 50% identity with the L-CDR3 of C2.

### Claim 3 (depends on 1)

The human monoclonal antibody of claim 1 which comprises a heavy chain having i) the H-CDR1 of C2, ii) the H-CDR2 of C2 and iii) the H-CDR3 of C2.

### Claim 4 (depends on 1)

The human monoclonal antibody of claim 1 which comprises a light chain having i) the L-CDR1 of C2, ii) the L-CDR2 of C2 and iii) the L-CDR3 of C2.

### Claim 5 (depends on 1)

The human monoclonal antibody of claim 1 which comprises a heavy chain having i) the H-CDR1 of C2, ii) the H-CDR2 of C2 and iii) the H-CDR3 of C2 and a light chain having i) the L-CDR1 of C2, ii) the L-CDR2 of C2 and iii) the L-CDR3 of C2.

### Claim 6 (depends on 1)

The human monoclonal antibody of claim 1 which is an antibody comprising a heavy chain having at least 70% identity with SEQ ID NO:1.

### Claim 7 (depends on 1)

The human monoclonal antibody of claim 1 which is an antibody comprising a light chain having at least 70% identity with SEQ ID NO:2.

### Claim 8 (depends on 1)

The human monoclonal antibody of claim 1 which is an antibody comprising a heavy chain having at least 70% identity with SEQ ID NO:1 and a light chain having at least 70% identity with SEQ ID NO:2.

### Claim 9 (depends on 1)

The human monoclonal antibody of claim 1 which is an antibody comprising a heavy chain which is identical to SEQ ID NO:1.

### Claim 10 (depends on 1)

The human monoclonal antibody of claim 1 which is an antibody comprising a light chain identical to SEQ ID NO:2.

### Claim 11 (depends on 1)

The human monoclonal antibody of claim 1 which is an antibody comprising a heavy chain identical to SEQ ID NO:1 and a light chain identical to SEQ ID NO:2.

### Claim 12 (depends on 1)

A fragment of the human monoclonal antibody of claim 1 which is selected from the group consisting of Fv, Fab, F(ab′)2, Fab′, dsFv, scFv, sc(Fv)2 and diabodies.

### Claim 13 (depends on 1)

A nucleic acid molecule which encodes a heavy chain and/or a light chain of the human monoclonal antibody of claim 1.

### Claim 14 (depends on 13)

A vector comprising the nucleic acid molecule of claim 13.

### Claim 15 (depends on 13)

A host cell comprising the nucleic acid molecule of claim 13.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

A method of treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the human monoclonal antibody of claim 1.

### Claim 18 (depends on 1)

A pharmaceutical composition which comprises the human monoclonal antibody of claim 1.

### Claim 19 (depends on 14)

A host cell comprising the vector of claim 14.
